Results 161 to 170 of about 38,022 (310)
Abstract Aims Once‐weekly (OW) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta‐analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrating new findings from the five large trials published in 2025.
Olivier Bourron, Damien Denimal
wiley +1 more source
Rethinking control‐IQ+ technology: Simple strategies for easy optimization
Abstract Control‐IQ+ is an automated insulin delivery (AID) algorithm approved for people with type 1 diabetes aged 2+ years and adults aged 18+ years with type 2 diabetes. While numerous publications support improved glycaemia and quality of life for people with diabetes, this practice paper is intended to encourage uptake for healthcare professionals
Viral N. Shah +5 more
wiley +1 more source
GLP-1 receptor agonist use in patients with psoriasis or hidradenitis suppurativa. [PDF]
Granovsky R +5 more
europepmc +1 more source
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami +16 more
wiley +1 more source
Unmasking an insulinoma: recurrent Hypoglycemia in a young patient following GLP-1 receptor agonist therapy -A case report. [PDF]
Baldera-Rodriguez N +5 more
europepmc +1 more source
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen +7 more
wiley +1 more source
An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller +7 more
wiley +1 more source
Digital engagement enhances dual GIP/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. [PDF]
Johnson H, Clift AK, Reisel D, Huang DR.
europepmc +1 more source
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay +19 more
wiley +1 more source
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. [PDF]
Zaitoon H +3 more
europepmc +1 more source

